story of the week
Natalizumab vs Fingolimod in Active Relapsing MS
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Multiple Sclerosis (Houndmills, Basingstoke, England)
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
BEST-MS: A Prospective Head-to-Head Comparative Study of Natalizumab and Fingolimod in Active Relapsing MS
Mult. Scler. 2020 Oct 30;[EPub Ahead of Print], M Cohen, L Mondot, F Bucciarelli, B Pignolet, DA Laplaud, S Wiertlewski, B Brochet, A Ruet, G Defer, N Derache, P Vermersch, H Zephir, M Debouverie, G Mathey, E Berger, C Cappé, P Labauge, C Carra, J De Seze, K Bigaut, D Brassat, C Lebrun-FrenayFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.